Live attenuated strain of
A live attenuated strain of S. pneumoniae containing at least two genes or operons that have disrupted expression or encode for proteins that have impaired function, the two genes or operons being fhs, piaA, proABC, spxB, Sp_1288 and Sp_1027. Pharmaceutical compositions containing the live attenuated strains are also described. The live attenuated strains and pharmaceutical compositions can be used to boost immunity in a subject and prevent S. pneumoniae infection.
1 . A live attenuated strain of Streptococcus pneumoniae , the live attenuated strain comprising at least two genes or operons that have disrupted expression or encode for a protein with impaired function, wherein the at least two genes or operons are selected from fhs, piaA, proABC, spxB, Sp_1288, and Sp_1027.
2 . The live attenuated strain of claim 1 , wherein the live attenuated strain is able to colonise the nasopharynx to a level which is at least 50% of the level observed for the wild-type strain.
3 . The live attenuated strain according to claim 1 , wherein the at least two genes or operons include fhs in combination with at least one of piaA, proABC, spxB, Sp_1288 and Sp_1027.
4 . The live attenuated strain according to claim 1 , wherein the at least two genes or operons are piaA and fhs.
5 . The live attenuated strain according to according to claim 1 , wherein the at least two genes or operons are fhs and Sp_1288.
6 . The live attenuated strain according to claim 1 , wherein the live attenuated strain does not contain a disrupted piuA gene.
7 . The live attenuated strain according to claim 1 , wherein the at least two genes or operons have disrupted expression, and wherein the expression of the at least two genes or operons is reduced by at least about 50% as compared to a wild-type strain.
8 . The live attenuated strain according to claim 7 , wherein the reduction in expression is determined by RNA-seq or by reverse transcriptase PCR.
9 . The live attenuated strain according to claim 1 , wherein the disrupted expression of the at least two genes or operons is caused by deletion and/or mutation of the at least to genes or operons or a portion thereof.
10 . The live attenuated strain according to claim 7 , wherein the disrupted expression of the at least two genes or operons is caused by biochemical inhibition of expression or function of the at least two genes or operons.
11 . The live attenuated strain according to claim 1 , wherein the at least two genes or operons encode for a protein with impaired function, and wherein the impaired function of the protein encoded by the at least two genes or operons is caused by the deletion and/or mutation of the at least two genes or operons or a portion thereof.
12 . A pharmaceutical composition comprising at least one live attenuated strain of Streptococcus pneumoniae according to claim 1 .
13 . A pharmaceutical composition comprising two or more different live attenuated strains of Streptococcus pneumoniae according to claim 1 , wherein the two or more different live attenuated strains are of a different serotype.
14 . A pharmaceutical composition according to claim 12 , further comprising at least one of a pharmaceutically acceptable adjuvant, excipient, diluent or carrier.
15 . A pharmaceutical composition according to claim 12 , wherein the pharmaceutical composition is formulated as a spray, optionally a nasal spray.
16 . A method of ameliorating infection and/or enhancing immunity in a subject, comprising:
administering to a subject in need thereof a therapeutically effective amount of a live attenuated strain of Streptococcus pneumoniae or a pharmaceutical composition of the live attenuated strain of Streptococcus pneumoniae;
wherein the live attenuated strain of Streptococcus pneumoniae comprises at least two genes or operons that have disrupted expression or encode for a protein with impaired function and wherein the at least two genes or operons are selected from fhs, piaA, proABC, spxB, Sp_1288, and Sp_1027.
17 . The method of claim 16 , wherein the live attenuated strain or pharmaceutical composition prevents nasopharyngeal colonization of S. pneumoniae in a subject.
18 . The method of claim 16 , wherein, the infection is:
i) a Streptococcus pneumoniae infection,
ii) pneumonia connected with S. pneumoniae
iii) septicemia connected with S. pneumoniae,
iv) meningitis connected with S. pneumoniae
v) an exacerbation of chronic obstructive pulmonary disease (COPD) connected with S. pneumoniae
vi) acute bronchitis connected with S. pneumoniae
vii) acute sinusitis connected with S. pneumoniae or
viii) acute otitis media connected with S. pneumoniae.
19 . The method of claim 18 , wherein the S. pneumoniae infection is of homologous serotype to the serotype of the live attenuated strain.
20 . The method of claim 18 , wherein the S. pneumoniae infection is of heterologous serotype to the serotype of the live attenuated strain.
21 . The method of claim 16 , wherein the method comprises administering the live attenuated strain or the pharmaceutical composition to the upper airway of the subject.
22 . The method of claim 16 , wherein the method comprises administering the live attenuated strain or the pharmaceutical composition intranasally, nasopharyngeally, to the oropharynx, subcutaneously, intradermally, intramuscularly, or a combination thereof.
23 . The method of claim 16 , wherein the subject is a human.
24 . The method of claim 16 , wherein the method prevents nasopharyngeal colonisation, lung infection, and/or bacteraemia.